NCT07191821View on ClinicalTrials.gov

TSPO Modulation in AD

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 8, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

June 1, 2027

Conditions
Alzheimer s Disease
Interventions
DRUG

XBD173

Small molecule experimental medication binding to mitochondrial protein TSPO

Trial Locations (1)

W12 0HS

NIHR Imperial CRF, London

All Listed Sponsors
lead

Imperial College London

OTHER

NCT07191821 - TSPO Modulation in AD | Biotech Hunter | Biotech Hunter